4892 Cyfuse Biomedical K.K. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4892

TSE Growth

Cyfuse Biomedical K.K.

620

JPY

-10

(-1.59%)

Mar 13, 3:30 pm JST

3.88

USD

Mar 13, 2:30 am EDT

Result

PTS

outside of trading hours

ー

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2022	374	-425	-433	-473	-178.1	0	Feb 14, 2023	J-GAAP
Dec, 2023	61	-697	-586	-589	-75.4	0	Feb 14, 2024	J-GAAP
Dec, 2024	54	-896	-869	-872	-108.3	0	Feb 14, 2025	J-GAAP
Dec, 2025	230	-828	-761	-763	-86.8	0	Feb 13, 2026	J-GAAP
Dec, 2026 Guidance	278	-1,081	-1,056	-1,059	-106.2	0	Feb 13, 2026	J-GAAP
YoY	+20.9%	-30.6%	-38.8%	-38.8%	-22.4%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Dec, 2022	Dec 1, 2022	367	-500	-476	-518	0*	J-GAAP
Results	Feb 14, 2023	374	-425	-433	-473	0*	J-GAAP
Dec, 2023	Feb 14, 2023	Available in future release
	Nov 14, 2023
	Jan 25, 2024
Results	Feb 14, 2024
Dec, 2024	Feb 14, 2024
	Nov 14, 2024
Results	Feb 14, 2025
Dec, 2025	Feb 14, 2025
	Jan 22, 2026
Results	Feb 13, 2026
Dec, 2026	Feb 13, 2026	278	-1,081	-1,056	-1,059	0	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Dec, 2017	78	－	Available in future release
Dec, 2018	26	-66.7
Dec, 2019	121	+365.4
Dec, 2020	137	+13.2
Dec, 2021	708	+416.8
Dec, 2022	374	-47.2
Dec, 2023	61	-83.7
Dec, 2024	54	-11.5
Dec, 2025	230	+325.9
Dec, 2026 Guidance	278	+20.9	-1,081	-30.6	-1,056	-38.8	-106.2	-22.4

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Dec, 2024	54	-896	-1,659	-30.62	-22.56	0.01	-108.3
Dec, 2025	230	-828	-360	-29.64	-19.60	0.06	-86.8
Dec, 2026 Guidance	278	-1,081	-389	-39.87	-24.82	0.07	-106.2

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	708	70	144	142	285.5
Fiscal Year	Dec, 2021	Dec, 2021	Dec, 2021	Dec, 2021	Dec, 2021

First Half

Result

Guidance History

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jan - Jun, 2023	18	-363	-362	-364	-46.7	0	Aug 14, 2023	J-GAAP
Jan - Jun, 2024	18	-448	-445	-447	-56.2	0	Aug 14, 2024	J-GAAP
Jan - Jun, 2025	29	-471	-401	-402	-48.9	0	Aug 14, 2025	J-GAAP
Jan - Jun, 2026 Guidance	ー	ー	ー	ー	－	0	Feb 13, 2026	J-GAAP
YoY	－	－	－	－	－

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Jun, 2023	Feb 14, 2023	ー	ー	ー	ー	0	J-GAAP
- - - - Results	Aug 14, 2023	18	-363	-362	-364	0	J-GAAP
Jun, 2024	Feb 14, 2024	Available in future release
Results	Aug 14, 2024
Jun, 2025	Feb 14, 2025
Results	Aug 14, 2025
Jun, 2026	Feb 13, 2026	ー	ー	ー	ー	0	J-GAAP

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Dec, 2023	-697	-581	-562	-19	18	2,873	68.18	J-GAAP
Dec, 2024	-896	-768	-760	-8	-52	2,052	58.33	J-GAAP
Dec, 2025	-828	-931	-534	-397	1,256	2,376	55.70	J-GAAP

Actual Performance and Financial Trends

Historical Performance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2023	61	-697	-586	-589	-75.4	0	Feb 14, 2024	J-GAAP
Dec, 2024	54	-896	-869	-872	-108.3	0	Feb 14, 2025	J-GAAP
Dec, 2025	230	-828	-761	-763	-86.8	0	Feb 13, 2026	J-GAAP
YoY	+325.9%	+7.6%	+12.4%	+12.5%	+19.9%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Jan - Mar, 2024	10	-229	-223	-224	-28.4	-2,290.0	May 15, 2024	J-GAAP
Apr - Jun, 2024	8	-219	-222	-223	-28.0	-2,737.5	Aug 14, 2024	J-GAAP
Jul - Sep, 2024	8	-226	-217	-217	-27.1	-2,825.0	Nov 14, 2024	J-GAAP
Oct - Dec, 2024	28	-222	-207	-208	-25.8	-792.9	Feb 14, 2025	J-GAAP
Jan - Mar, 2025	24	-240	-162	-162	-19.9	-1,000.0	May 15, 2025	J-GAAP
Apr - Jun, 2025	5	-231	-239	-240	-29.2	-4,620.0	Aug 14, 2025	J-GAAP
Jul - Sep, 2025	32	-218	-234	-235	-27.6	-681.3	Nov 14, 2025	J-GAAP
Oct - Dec, 2025	169	-139	-126	-126	-14.3	-82.2	Feb 13, 2026	J-GAAP
YoY	+503.6%	+37.4%	+39.1%	+39.4%	+44.5%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Jul - Sep, 2022	8	－	Available in future release
Oct - Dec, 2022	34	－
Jan - Mar, 2023	7	－
Apr - Jun, 2023	11	－
Jul - Sep, 2023	11	+37.5
Oct - Dec, 2023	32	-5.9
Jan - Mar, 2024	10	+42.9
Apr - Jun, 2024	8	-27.3
Jul - Sep, 2024	8	-27.3
Oct - Dec, 2024	28	-12.5
Jan - Mar, 2025	24	+140.0
Apr - Jun, 2025	5	-37.5
Jul - Sep, 2025	32	+300.0
Oct - Dec, 2025	169	+503.6	-139	+37.4	-126	+39.1	-14.3	+44.6

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	169	-139	-54	-55	-7.0
Fiscal Year	Dec, 2025	Dec, 2025	Dec, 2023	Dec, 2023	Dec, 2023

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Dec, 2023	405.71	76.0	4,214	3,202	-1,986	0.29	Feb 14, 2024	J-GAAP
Dec, 2024	304.60	70.9	3,518	2,493	-2,858	0.34	Feb 14, 2025	J-GAAP
Dec, 2025	276.42	62.3	4,266	2,656	-3,622	0.49	Feb 13, 2026	J-GAAP

Cyfuse Biomedical K.K.(4892) Financial Results